Your dog’s life stages: dog health from puppy to adult and senior
The needs of dogs change as they age. Find out how to take care of their health at all stages of life: from puppy to adult and senior.
Search
BI Access to Healthcare Strategy_Availability
Boehringer Ingelheim aspires to be a leader in ensuring improved access by delivering More Health to humans, animals and communities around the world. Read more about our holistic approach, based on partnerships and local empowerment.
New cancer therapeutics collaboration with 3T Bio
Boehringer Ingelheim and 3T Biosciences collaborate to discover and develop next-generation cancer therapies to address high unmet patient needs
NexGard COMBO for cats EMA marketing authorization
Boehringer Ingelheim received marketing authorization from the EMA (European Medicine Agency) for its NexGard® COMBO topical solution for cats.
New African Swine Fever Manual published
Boehringer Ingelheim joined forces with the leading veterinarians to fight African swine fever. The new African Swine Fever Knowledge Handbook published.
Positivity... just a paw away
Data released by Boehringer Ingelheim shows the 96% of dog owners and 91% of cat owners claim their pet has a positive impact on their daily lives.
Behavioral science to improve cattle well-being
Boehringer Ingelheim kicks off a project based on behavioral science to improve cattle well-being
T-cell engagers: Reawakening T-cells to fight cancer
Learn how we are taking cancer on through our approach to immuno-oncology and our T-cell engagers plarform
Access to Healthcare Strategy Innovation
Boehringer Ingelheim aspires to be a leader in ensuring improved access by delivering More Health to humans, animals and communities around the world. Read more about our holistic approach, based on partnerships and local empowerment.
2021 ABCD Young Scientist Award feline health
Young veterinary researchers Julia Klaus and Dr Yasmin Parr receive award for their work into feline SARS-CoV-2 infections and feline leukaemia virus.
Advance study vaccinating increased milk production
[New ADVANCE study shows vaccinating with Bovela® results in increased milk production
Access to Healthcare Strategy Sustainable Access Models
Boehringer Ingelheim aspires to be a leader in ensuring improved access by delivering more health to humans, animals and communities around the world. Read more about our holistic approach, based on partnerships and local empowerment.
Chicken Pot Pie Video
Another Taking Cancer on Through Flavour recipe that’s easy-to-eat, and high in energy and protein. Find out how it’s made.
Get in touch
Get in touch
Boehringer Ingelheim attends WVPAC 2019
Boehringer Ingelheim attends and showcases its leading vaccines and services at 21st World Veterinary Poultry Association Congress
Partnering Vanderbilt WCNDD
Boehringer Ingelheim and the Warren Center for Neuroscience Drug Discovery are partnering to find new medicines for patients with neuropsychiatric disorders.
Launch of BVDzero scholarship for veterinary students
Launch of BVDzero scholarship for veterinary students globally
World-Psoriasis-Day-IFPA-Interview
Interview with the International Federation of Psoriasis Associations (IFPA)
Boehringer Ingelheim Access to Healthcare Strategy last mile
We aspire to be a leader in ensuring improved access by delivering more health to humans, animals and communities around the world.
Koropi
For more than 45 years, the company has been producing pharmaceuticals in its production facility in Koropi, Greece.
How dangerous is the mpox virus?
Mpox, formerly known as monkeypox: What exactly is this virus, how is it transmitted, and what are the most noticeable symptoms?
Celebrating 20 years of Metacam for cattle
Celebrating 20 years of Metacam (Meloxicam) for cattle
New exchange platform with Harbin Research Institute
Boehringer Ingelheim and Harbin Veterinary Research Institute set up ‘industry-academia-research’ exchange platform
12th Expert Forum on Farm Animal Well-Being
The 12th Expert Forum on Farm Animal Well-Being brought together over 100 industry experts
Trailr2-cdh17-antibody-phase1-trial
Boehringer Ingelheim advances a bi-specific therapeutic antibody to first-in-human clinical trial for patients with advanced gastrointestinal cancers